<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30112">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02714699</url>
  </required_header>
  <id_info>
    <org_study_id>HB-OH</org_study_id>
    <nct_id>NCT02714699</nct_id>
  </id_info>
  <brief_title>Oral Hyoscine Butyl Bromide Versus Diclofenac Potassium Before Office Hysteroscopy</brief_title>
  <official_title>Randomized Clinical Trial of Oral Hyoscine Butyl Bromide Versus Diclofenac Potassium in Reducing Pain During Office Hysteroscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to determine the efficacy of oral hyoscine butyl bromide versus diclofenac
      potassium on the pain scores during office hysteroscopy
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Participant</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean pain score during hysteroscopy</measure>
    <time_frame>intraoperative</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Endoscopy</condition>
  <arm_group>
    <arm_group_label>diclofenac potassium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral diclofenac potassium</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hyoscine butyl bromide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral hyoscine butyl bromide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>oral placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>diclofenac potassium</intervention_name>
    <description>patients will take oral diclofenac potassium; one tablet (cataflam 50 mg) and one tablet placebo 30 minutes before the procedure</description>
    <arm_group_label>diclofenac potassium</arm_group_label>
    <other_name>cataflam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hyoscine butyl bromide</intervention_name>
    <description>patients will take oral hyoscine butyl bromide; 2 tablets (buscopan 10 mg) 30 minutes before the procedure</description>
    <arm_group_label>hyoscine butyl bromide</arm_group_label>
    <other_name>buscopan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>patients will take oral placebo; 2 tablets 30 minutes before the procedure</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients that must perform a diagnostic hysteroscopy.

          2. Acceptance to participate in the study.

          3. Signed informed consent.

          4. Not taking analgesics (acetaminophen, ibuprofen, mefenamic acid) before admission.

          5. Absence of sedative use before admission

        Exclusion Criteria:

          1. Hypersensitivity to drugs

          2. refusal of the patient

          3. Patients are pregnant.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ahmed Abbas</name>
      <address>
        <city>Assiut</city>
        <state>Cairo</state>
        <zip>002</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ahmed abbas, MD</last_name>
      <email>bmr90@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>ahmed abbas</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 12, 2017</lastchanged_date>
  <firstreceived_date>March 16, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Ahmed Mohamed Abbas</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Butylscopolammonium Bromide</mesh_term>
    <mesh_term>Scopolamine Hydrobromide</mesh_term>
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
